



Contents lists available at ScienceDirect

Bioorganic & Medicinal Chemistry

journal homepage: www.elsevier.com/locate/bmc



Synthesis and biological evaluation of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors



Ramakrishna Edupuganti^{a,b,†}, Qiantao Wang^{a,d,†}, Clint D. J. Tavares^{c,†}, Catrina A. Chitjian^c, James L. Bachman^b, Pengyu Ren^d, Eric V. Anslyn^{b,*}, Kevin N. Dalby^{a,c,*}

^a Division of Medicinal Chemistry, College of Pharmacy, The University of Texas at Austin, TX 78712, USA

^b Department of Chemistry, The University of Texas at Austin, TX 78712, USA

^c Graduate Program in Cell and Molecular Biology, The University of Texas at Austin, TX 78712, USA

^d Department of Biomedical Engineering, Cockrell School of Engineering, College of Engineering, The University of Texas at Austin, TX 78712, USA

ARTICLE INFO

Article history:

Received 5 May 2014

Revised 19 June 2014

Accepted 20 June 2014

Available online 30 June 2014

Keywords:

Pyrido[2,3-*d*]pyrimidine-2,4-dione

Uracil

eEF-2K inhibitor

Kinase inhibitor

Homology modeling

ABSTRACT

A small molecule library of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **6–16** was synthesized from 6-amino-1,3-disubstituted uracils **18**, characterized, and screened for inhibitory activity against eukaryotic elongation factor-2 kinase (eEF-2K). To understand the binding pocket of eEF-2K, structural modifications of the pyrido[2,3-*d*]pyrimidine were made at three regions (*R*¹, *R*², and *R*³). A homology model of eEF-2K was created, and compound **6** (A-484954, Abbott laboratories) was docked in the catalytic domain of eEF-2K. Compounds **6** (IC₅₀ = 420 nM) and **9** (IC₅₀ = 930 nM) are found to be better molecules in this preliminary series of pyrido[2,3-*d*]pyrimidine analogs. eEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compound **6**, to a lesser extent by compound **9**, and is unaffected by compound **12**. Similar inhibitory results are observed when eEF-2K activity is stimulated by 2-deoxy-D-glucose (2-DOG) treatment, suggesting that compounds **6** and **9** are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent. The results of this work will shed light on the further design and optimization of novel pyrido[2,3-*d*]pyrimidine analogs as eEF-2K inhibitors.

© 2014 Elsevier Ltd. All rights reserved.

1. Introduction

Eukaryotic elongation factor-2 kinase (eEF-2K, EC 2.7.11.20) is an atypical Ser/Thr-protein kinase, and is also known as a calcium/calmodulin-dependent protein kinase-III (CaM kinase-III). eEF-2K is not structurally similar to conventional protein kinases, and the structure of eEF-2K has not been reported. eEF-2K phosphorylates eEF-2 at Thr-56 and Thr-58, and inactivates eEF-2, and thus regulates protein synthesis at the elongation step of translation.^{1,2} Nutrients and growth factors inactivate eEF-2K whereas starvation activates it.³ In 2013, Lepruvier et al.⁴ demonstrated a crucial role for eEF-2K in protecting normal cells from nutrient deprivation through inhibition of eEF-2, and they suggested how cancer cells could exploit this pathway by activating

Abbreviations: eEF-2K, eukaryotic elongation factor-2 kinase; 2-DOG, 2-deoxy-D-glucose; DMF, dimethylformamide; DMSO, dimethylsulfoxide.

* Corresponding authors. Tel.: +1 (512) 471 0068; fax: +1 (512) 471 7791 (E.V.A.); tel.: +1 (512) 471 9267; fax: +1 (512) 232 2606 (K.N.D.).

E-mail addresses: anslyn@austin.utexas.edu (E.V. Anslyn), dalby@austin.utexas.edu (K.N. Dalby).

[†] R. Edupuganti, Q. Wang, and C.D.J. Tavares contributed equally to this work.

<http://dx.doi.org/10.1016/j.bmc.2014.06.050>

0968-0896/© 2014 Elsevier Ltd. All rights reserved.

eEF-2K to adapt to metabolic stress. eEF-2K has been reported to be upregulated in various malignant cells such as breast cancer cells,⁵ malignant glioma cells,⁶ HL60 leukemia cells,⁷ and pancreatic cancer (PaCa) cells,⁸ and has been identified as a potential cancer-therapeutic target.⁹

Several small molecule inhibitors of eEF-2K have been reported (Fig. 1), including: Rottlerin **1**, which is found to be a non specific and cytotoxic inhibitor,¹⁰ 1,3-selenazine analog **2**, which is suggested to block phosphorylation of eEF-2 in cells and to react with cysteine residues,¹¹ the imidazolium derivative (NH125) **3**,¹² which does not inhibit eEF-2K in cells,^{13,16} and thieno[2,3-*b*]pyridine **4**, which is an ATP-competitive inhibitor that lacks potency in cells.¹⁴ Recently, high-throughput screens for eEF-2K inhibitors by us,¹⁵ and by Abbott laboratories,¹⁶ revealed thiopyran-dicarbonyl nitrile analog **5**, and pyrido-pyrimidinedione derivative A-484954 (compound **6**), respectively. A-484954, a small molecule discovered by Abbott, is an ATP-competitive and cell-permeable inhibitor of eEF-2K (IC₅₀ = 0.28 μM).

We are interested in developing a more potent and selective eEF-2K inhibitor to probe the function of eEF-2K in the regulation of protein synthesis. In this paper, we report the synthesis of a





Figure 1. Structures of eEF-2K inhibitors.

preliminary series of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **6–16** and their inhibitory activity against eEF-2K to explore structure–activity relationships (SAR) of A-484954. Moreover, a homology model has been generated and used to dock compound **6** to provide insight into its binding in the catalytic domain of eEF-2K.

2. Results and discussion

2.1. Chemistry

Pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **6–16** were prepared according to Schemes 1–3. Direct alkylation of commercially available uracil derivatives **17** with either ethyl iodide or *n*-propyl iodide in the presence of 10–15% aqueous NaOH afforded the corresponding 1,3-disubstituted-6-aminouracils **18c–18e** in 40–53% yield (Scheme 1).¹⁷ To construct the pyridine ring of pyrido[2,3-*d*]pyrimidine **6**, uracil **18c** was treated with the Vilsmeier reagent **19**, which was generated in situ from phosphoryl chloride in dimethyl formamide, followed by solvent evaporation and treatment of the residue with triethylamine and cyanoacetamide in ethanol.¹⁸ However, addition of traces of water present in the reaction mixture to the hydrochloride salt **20c** resulted in hydrolyzed product **21** in 66% yield, but not the required pyrido[2,3-*d*]pyrimidine **6** (Scheme 2).



Scheme 1. Alkylation of uracil derivatives **17**.

Alternatively, when a catalytic amount of dimethyl formamide and oxalyl chloride were used to prepare the Vilsmeier reagent **22**, and the resulting HCl salt **20** was treated with triethylamine and cyanoacetamide in ethanol, compound **6** was isolated in 78% yield over the two steps (Scheme 3). Other pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **7**, **9**, **12–16** were also synthesized using this procedure. Compound **8** was isolated in 47% yield by direct methylation of compound **7** in presence of KO^tBu as a base. On treatment with sodium hydride and *p*-nitrobenzylbromide, compound **7** resulted in 61% of benzylated product **10** as an off-white solid, which was reduced with SnCl₂ in an ethyl acetate and methanol mixture to afford amine **11** in 70% yield.

2.2. Computer homology modeling



The structure of eEF-2K was generated using homology modeling with *Dictyostelium* myosin heavy chain kinase A (MHCK A) as the template, and compound **6** was docked into the ATP-binding pocket of eEF-2K (Fig. 2). The inhibitor **6** is shown in cyan. The protein is shown in cartoon representation, with the hinge region in purple and the Gly-rich loop in blue. The binding of inhibitor **6** involves hydrogen bonds to residues K170, I232 and G234. The hydrophobic cyclopropyl and ethyl groups are buried deep inside the adenine-binding pocket and underneath the Gly-rich-loop, respectively. Docking was performed using Gold5.1¹⁹ with ChemPLP fitness function.²⁰ Twenty independent docking attempts were performed for the ligand using generic algorithm. The results of each attempt were ranked according to the ChemPLP fitness score and were virtually inspected. The highest ranked pose of the ligand also happened to be very similar to the most of the high-ranking poses that resulted from the twenty attempts (data not shown). This suggested that the docking attempts reach an optimal state, and thus supporting the likelihood of this pose in docking. Details on generating the homology model can be found in our recent work.²¹

2.3. Biological activity

2.3.1. In vitro activity against recombinant eEF-2K

It has been reported that compound **6** (A-484954, Abbott labs), inhibits eEF-2K activity in vitro with an IC₅₀ value of 0.28 μM.¹⁶ In addition to compound **6**, we examined a series of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives (**7–16**) to evaluate their potential in terms of modification of the initial compound, and to probe their structure–activity relationships. A radioactive assay utilizing [γ-³²P]ATP was used to assess the inhibition of recombinant human eEF-2K by the compounds, where kinase activity was determined by measuring the rate of incorporation of ³²P into a peptide substrate.^{22,23}

The inhibition found for target compounds **6–16**, **18c**, and **21** against recombinant eEF-2K activity in vitro are summarized in Table 1. Compound **6** has an IC₅₀ of 0.42 μM, which differs from the reported value of 0.28 μM (Fig. 3).¹⁶ This can be accounted for by the difference in assay conditions, where our assay uses 10 μM ATP compared to 5 μM ATP by Chen et al. Because the compound is reported to be an ATP-competitive inhibitor, it is expected that an increase in ATP concentration in the assay would increase the IC₅₀ value. When the R¹ group on the scaffold is modified from hydrogen to benzyl derivatives, the potency increased from hydrogen (IC₅₀ = 6.6 μM) to ethyl (IC₅₀ = 0.42 μM) and was then decreased to benzyl derivatives (IC₅₀ > 25 μM). Complete loss of inhibitory activity is observed on changing the CONH₂ group (IC₅₀ = 0.42 μM) to CSNH₂, CN and CO₂Et (compounds **12**, **13**, and **14**, respectively) (IC₅₀ > 25 μM). Moderate loss of activity is observed when the cyclopropyl group (IC₅₀ = 0.42 μM) at R³ is changed to an ethyl group (IC₅₀ = 1–2 μM). The inactivity of



Scheme 3. Synthesis of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **6–16**.





Figure 2. Compound **6** docked into the ATP-binding pocket of eEF-2K. (A) eEF-2K is rendered using solvent accessible surface and compound **6** (sticks) is shown well fitted into the pocket. (B) Docking determined the four key residues that are shown in sticks. Hydrogen bonds are shown as blue dashed lines.

Table 1In vitro activity of the target compounds **6–16**, **18c**, and **21** against eEF-2K


Compound	R ¹	R ²	R ³	IC ₅₀ (μM)
7	H	CONH ₂	Cyclopropyl	6.6 ± 0.2
8	Me	CONH ₂	Cyclopropyl	6.1 ± 0.2
6	Et	CONH ₂	Cyclopropyl	0.42 ± 0.01
9	<i>n</i> -Pr	CONH ₂	Cyclopropyl	0.93 ± 0.03
10	CH ₂ -Ph-NO ₂ - <i>p</i>	CONH ₂	Cyclopropyl	>25
11	CH ₂ -Ph-NH ₂ - <i>p</i>	CONH ₂	Cyclopropyl	>25
12	Et	CSNH ₂	Cyclopropyl	>25
13	Et	CO ₂ Et	Cyclopropyl	>25
14	Et	CN	Cyclopropyl	>25
15	Et	CONH ₂	Et	1–2
16	Me	CONH ₂	Me	>25
18c	—	—	—	>25
21	—	—	—	>25

Inhibitor dose response assays were performed with 5 nM recombinant eEF-2K enzyme at various concentrations of the inhibitor, in the presence of 50 μM free Ca²⁺, 200 nM CaM and 10 μM [γ-³²P]ATP, against 150 μM peptide substrate as described under the Section 4. The inhibitor was incubated with eEF-2K for 30 min at 30 °C before initiating the assay with peptide and [γ-³²P]ATP. Kinase activity in each case was determined by calculating the rate of phosphorylation of the peptide (μM/s), and dose-response curves for data conforming to inhibition were fit to Eq. 1.

compounds **18c** and **21** stresses the importance of a pyridine ring for this class of molecules. These results provide new insights, which may aid in the rational design of inhibitors for the kinase.

2.3.2. Cellular activity against eEF-2K

Chen et al. have reported that treatment of various cell lines with compound **6** inhibits eEF-2K activity in a dose-dependent manner, as indicated by reduced levels of phosphorylated eEF-2 (Thr-56).¹⁶ This was observed in human prostate cancer (PC3), human cervical cancer (HeLa), human non-small cell lung cancer (H460 and H1299), and rat glial (C6) cells. Their results are most

prominent under conditions of nutrient deprivation (Hanks' Balanced Salt Solution, HBSS), which is known to activate eEF-2K presumably through inhibition of the nutrient-sensitive mTOR pathway.^{16,24} To determine if similar inhibition was observed in breast cancer cells, compounds **6** (IC₅₀ = 0.42 μM), **9** (IC₅₀ = 0.93 μM), and **12** (IC₅₀ >25 μM) were assayed in the MDA-MB-231 cell line. The level of phosphorylated eEF-2 (Thr-56) was used to estimate the activity of eEF-2K, and as indicated in Figure 4, results of cellular inhibition are similar to the in vitro kinase assay data. In low-glucose (5.6 mM) media, eEF-2K activity is significantly reduced by the addition of compound **6**, to a lesser extent by compound **9**, and is unaffected by compound **12** (Fig. 4). To activate the AMPK-eEF-2K axis, 2-DOG was used. 2-DOG inhibits glycolysis and its production of ATP, thus activating AMPK, which in turn activates eEF-2K through phosphorylation at Ser-398.²⁵ Similar inhibitory results are observed when eEF-2K activity is stimulated by 2-DOG treatment (Fig. 4), suggesting that compounds **6** and **9** are able to inhibit AMPK-mediated activation of eEF-2K to a notable extent.




Figure 4. Cellular analysis of compounds against eEF-2K activity. MDA-MB-231 tumorigenic breast cells were treated with 75 μM compound **6**, **9**, or **12** for 1 h in low-glucose media ± 2-DOG, along with the appropriate controls, as described under the Section 4. One set of samples was stimulated with 25 mM 2-DOG (30 min) to activate the AMPK-eEF-2K axis. Cell lysates were then analyzed by Western blotting using antibodies specific for phospho-eEF-2 (Thr-56), total eEF-2, total eEF-2K and pan-Actin as described under the Section 4.




Figure 3. Inhibition of recombinant eEF-2K activity by compounds. Inhibitor dose response assays were performed with 5 nM eEF-2K enzyme at various concentrations of the inhibitor, in the presence of 50 μM free Ca²⁺, 200 nM CaM and 10 μM [γ-³²P]ATP, against 150 μM peptide substrate as described under the Section 4. The inhibitor was incubated with eEF-2K for 30 min at 30 °C before initiating the assay with peptide and [γ-³²P]ATP. Data are plotted as the percentage of kinase activity as a function of inhibitor concentration, and fit to Eq. 1. (A) Compound **6**. (B) Compound **9**.

3. Summary

In summary, a series of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives **6–16** was synthesized and screened against eEF-2K inhibitory activity. Ethyl group at R¹, CONH₂ at R² and cyclopropyl at R³ are found to be optimal, and the pyridine ring and CONH₂ group in **6** are essential for the activity of the studied compounds. Compounds **6** (IC₅₀ = 420 nM) and **9** (IC₅₀ = 930 nM) are found to be the best molecules in this preliminary series of pyrido[2,3-*d*]pyrimidine analogs. eEF-2K activity in MDA-MB-231 breast cancer cells is significantly reduced by compound **6**, and to a lesser extent by compound **9**. Because there is no eEF-2K crystal structure, the knowledge of the structural features from this preliminary series of analogs along with in-depth computer modeling should yield insights to develop a more potent eEF-2K inhibitor.

4. Experimental section

4.1. Chemistry

Reagents and starting materials including **17a**, **17b**, and **18f** were purchased from various commercial sources and used without further purification unless otherwise stated. All reactions were carried out in oven- or flame-dried glassware under argon. Thin-layer chromatography (TLC) was performed using pre-coated TLC plates with silica gel 60 F₂₅₄ (EMD) or with aluminum oxide 60 F₂₅₄ neutral. Flash column chromatography was performed using 40–63 μm (230–400 mesh ASTM) silica gel (EMD). Melting points were recorded on a Thomas Hoover capillary melting point apparatus. NMR spectra were recorded on a Varian MR spectrometer. High-resolution mass and liquid chromatography mass spectral data were obtained at the University of Texas at Austin. Compounds were characterized by NMR and HRMS or LCMS.

4.1.1. General procedure for the synthesis of 6-amino-1-alkyl-3-alkylpyrimidine-2,4(1*H*,3*H*)-dione (Compounds **18c–18e**)

A mixture of 6-amino-1-alkyl uracil **17** (1 mmol), sodium hydroxide 10–15% (0.3 mL) and 95% EtOH (0.9 mL) was heated under reflux for 15 min and cooled to room temperature. To the reaction mixture was added the corresponding alkylating agent (R¹-I) (2 mmol) dropwise. The resulting solution was heated under reflux for 3–8 h. The volatiles were removed under reduced pressure and the residue was partitioned between chloroform/water (2:1 ratio v/v, 9 mL). The organic layer was washed with water, brine, dried over Na₂SO₄ and evaporated to dryness to give the corresponding 3-substituted 6-amino-1-alkyl-uracils **18c–18e**. Unreacted starting material was recovered from the aqueous phase by evaporation to dryness. The obtained crude from organic layer was purified by flash chromatography using 0–10% methanol in dichloromethane.

4.1.1.1. 6-Amino-1-cyclopropyl-3-ethylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **18c).** Prepared from 6-amino-1-cyclopropylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **17a**) and ethyl iodide in 40% yield as a white solid. Mp 186–187 °C. ¹H NMR (400 MHz, CDCl₃): δ 4.91 (s, 1H), 4.90 (br s, 2H), 3.93 (q, *J* = 7.0 Hz, 2H), 2.66 (m, 1H), 1.24 (m, 2H), 1.19 (t, *J* = 7.0 Hz, 3H), 0.99 (m, 2H). LCMS: *m/z* [M+H]⁺ 196.2.

4.1.1.2. 6-Amino-1-cyclopropyl-3-propylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **18d).** Prepared from 6-amino-1-cyclopropylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **17a**) and propyl iodide in 53% yield as a white solid. Mp 154–155 °C. ¹H NMR (400 MHz, CDCl₃): δ 4.90 (s, 1H), 4.87 (br s, 2H), 3.88–3.70 (m, 2H),

2.72–2.60 (m, 1H), 1.61 (m, 2H), 1.24 (m, 2H), 1.01–0.95 (m, 2H), 0.92 (t, *J* = 7.5 Hz, 3H). LCMS: *m/z* [M+H]⁺ 210.2.

4.1.1.3. 6-Amino-1,3-diethylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **18e).** Prepared from 6-amino-1-ethylpyrimidine-2,4(1*H*,3*H*)-dione (Compound **17b**) and ethyl iodide in 42% yield as a white solid. Mp 192–193 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 6.79 (br s, 2H), 4.64 (s, 1H), 3.82 (q, *J* = 7.0 Hz, 2H), 3.73 (q, *J* = 7.0 Hz, 2H), 1.09 (t, *J* = 7.0 Hz, 3H), 1.02 (t, *J* = 7.0 Hz, 3H). LCMS: *m/z* [M+H]⁺ 184.4.

4.1.2. Synthesis of 6-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidine-5-carbaldehyde (Compound **21**)

To a suspension of **18c** (20 mg, 0.102 mmol) in DMF (0.6 mL) was added phosphoryl chloride (10 μL, 0.113 mmol) dropwise at below 20 °C. The reaction mixture was stirred for 30 min at room temperature. After evaporation of volatiles, the crude was taken to the next step. To a mixture of the crude in ethanol (1 mL) was added cyanoacetamide (9 mg, 0.102 mmol) and then triethylamine (17 μL, 0.123 mmol) dropwise at 0 °C. The suspension was stirred for 2 h at room temperature. Solvent was removed and the obtained crude was purified by flash chromatography using 0–5% methanol in dichloromethane to afford **21** as a white solid in 66% yield. Mp 149–150 °C. ¹H NMR (400 MHz, CDCl₃): δ 10.63 (br s, 1H), 9.93 (s, 1H), 6.19 (br s, 1H), 3.97 (q, *J* = 7.2 Hz, 2H), 2.67 (m, 1H), 1.33 (m, 2H), 1.21 (t, *J* = 7.2 Hz, 3H), 1.00 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 188.8, 162.1, 157.9, 150.2, 91.3, 36.2, 23.5, 13.1, 9.1. LCMS: *m/z* [M+H]⁺ 224.2.

4.1.3. General procedure for the synthesis and characterization of pyrido[2,3-*d*]pyrimidine-2,4-dione derivatives (Compounds **6**, **7**, **9**, **12–16**)

To a solution of dimethylformamide (0.11 mmol) in dichloromethane (1.5 mL) was added oxalyl chloride (0.11 mmol) dropwise at ca. 10 °C. The reaction mixture was stirred for 30 min at room temperature. Compound **18** (0.10 mmol) was added to the resulting white suspension and stirred for another 30 min. Volatiles were removed and the crude was taken to the next step without further purification. To the mixture of the crude in dry ethanol (1.0 mL) was added an active methylene compound such as cyanoacetamide, cyanothioacetamide, ethyl cyanoacetate, or malononitrile (0.10 mmol) and then triethylamine (0.12 mmol) dropwise at 0 °C. The suspension was allowed to room temperature and stirred for 2 h. Filtered the resulting precipitate and washed with ethanol. In the case of no precipitation, solvent was removed and the obtained crude was purified by flash chromatography (either neutral Al₂O₃ or silica gel) using 0–10% methanol in dichloromethane.

4.1.3.1. Synthesis of 7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-*d*]pyrimidine-6-carboxamide (Compound **6**).

Isolated in 78% yield as a white solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.55 (s, 1H), 8.22 (s, 2H), 7.36 (s, 2H), 3.89 (q, *J* = 8.0 Hz, 2H), 2.76 (m, 1H), 1.11 (t, *J* = 8.0 Hz, 3H), 1.08 (m, 2H), 0.86–0.71 (m, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.8, 161.1, 160.0, 153.6, 151.1, 138.3, 105.4, 99.5, 35.7, 25.8, 13.1, 9.7. HRMS: *m/z* calcd for C₁₃H₁₅N₅O₃ [M]⁺ 289.1175, found 289.1182.

4.1.3.2. Synthesis of 7-amino-1-cyclopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-*d*]pyrimidine-6-carboxamide (Compound **7**).

Isolated in 81% yield as a yellow solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 11.17 (s, 1H), 8.51 (s, 1H), 8.20 (s, 1H), 7.33 (s, 1H), 2.70 (m, 1H), 1.14–0.98 (m, 2H), 0.85–0.73 (m, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆): δ 168.8, 161.2, 160.9, 154.9, 151.1, 137.9, 105.0, 100.0, 25.0, 9.4. LCMS: *m/z* [M+H]⁺ 262.1.

4.1.3.3. Synthesis of 7-amino-1-cyclopropyl-2,4-dioxo-3-propyl-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 9).

Isolated in 66% yield as a white solid. Mp 234–235 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.54 (s, 1H), 8.23 (s, 1H), 7.36 (s, 1H), 3.91–3.72 (m, 2H), 2.77 (m, 1H), 1.64–1.46 (m, 2H), 1.17–1.02 (m, 2H), 0.86 (t, *J* = 7.4 Hz, 3H), 0.81–0.71 (m, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.9, 161.1, 160.2, 153.6, 151.3, 138.4, 105.4, 99.4, 42.1, 25.8, 20.8, 11.3, 9.9. HRMS: *m/z* calcd for C₁₄H₁₇N₅O₃ [M]⁺ 303.1331, found 303.1331.

4.1.3.4. Synthesis of 7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carbothioamide (Compound 12).

Isolated in 73% yield as a yellow solid. Mp 222–223 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 9.74 (d, *J* = 69.6 Hz, 2H), 8.11 (d, *J* = 1.9 Hz, 1H), 8.02 (br s, 1H), 3.89 (dd, *J* = 7.1, 2.0 Hz, 1H), 2.77 (m, 1H), 1.11 (m, 2H), 0.79 (m, 2H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 196.5, 160.1, 159.3, 152.7, 151.1, 135.6, 114.0, 99.3, 35.8, 25.8, 13.1, 9.6. LCMS: *m/z* [M+H]⁺ 306.0.

4.1.3.5. Synthesis of ethyl 7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxylate (Compound 13).

Isolated in 65% yield as a white solid. Mp 220–221 °C. ¹H NMR (400 MHz, CDCl₃): δ 8.85 (s, 1H), 8.23 (s, 1H), 5.73 (s, 1H), 4.35 (q, *J* = 7.1 Hz, 2H), 4.06 (q, *J* = 7.1 Hz, 2H), 2.82 (m, 1H), 1.39 (t, *J* = 7.1 Hz, 3H), 1.27–1.23 (m, 3H), 1.23–1.19 (m, 2H), 0.90–0.83 (m, 2H). ¹³C NMR (100 MHz, CDCl₃): δ 166.3, 161.1, 160.5, 154.8, 151.7, 142.4, 103.1, 101.8, 61.2, 36.8, 26.1, 14.3, 13.2, 9.9. LCMS: *m/z* [M+H]⁺ 319.2.

4.1.3.6. Synthesis of 7-amino-1-cyclopropyl-3-ethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carbonitrile (Compound 14).

Isolated in 79% yield as an off-white solid. Mp 189–190 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.32 (s, 1H), 7.80 (br s, 2H), 3.86 (m, 2H), 2.74 (m, 1H), 1.37–0.90 (m, 5H), 0.89–0.57 (m, 2H). LCMS: *m/z* [M+H]⁺ 272.2.

4.1.3.7. Synthesis of 7-amino-1,3-diethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 15).

Isolated in 61% yield as a light yellow solid. Mp 249–250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.58 (s, 1H), 8.24 (br s, 2H), 7.37 (br s, 2H), 4.17 (q, *J* = 6.9 Hz, 2H), 3.92 (q, *J* = 7.0 Hz, 2H), 1.19 (t, *J* = 6.9 Hz, 3H), 1.13 (t, *J* = 6.9 Hz, 3H). ¹³C NMR (100 MHz, DMSO-*d*₆): δ 168.8, 161.5, 159.7, 151.8, 150.3, 138.6, 105.5, 99.1, 36.7, 35.8, 13.1. HRMS: *m/z* calcd for C₁₂H₁₅N₅O₃ [M]⁺ 277.1175, found 277.1177.

4.1.3.8. Synthesis of 7-amino-1,3-dimethyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 16).

Isolated in 72% yield as a light yellow solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.59 (s, 1H), 8.25 (br s, 2H), 7.37 (br s, 2H), 3.46 (s, 3H), 3.25 (s, 3H). LCMS: *m/z* [M+H]⁺ 250.2.

4.1.3.9. Synthesis of 7-amino-1-cyclopropyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 8).

To a mixture of **7** (30 mg, 0.191 mmol) in DMF (2 mL) was added KO^tBu (19.3 mg, 0.172 mmol) and methyl iodide (11 μL, 0.172 mmol) at room temperature. After stirring for 12 h, volatiles were removed under reduced pressure and the residue was purified by flash chromatography (neutral Al₂O₃) using 0–5% methanol in dichloromethane to obtain **8** in 47% yield as an off-white solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.56 (s, 1H), 8.24 (s, 2H), 7.35 (s, 2H), 3.22 (s, 3H), 2.77 (m, 1H), 1.17–1.01 (m, 2H), 0.79 (m, 2H). ¹³C NMR (150 MHz, DMSO-*d*₆): δ 168.8, 161.1, 160.4, 153.5, 151.6, 138.2, 105.4, 99.5, 27.6, 25.9, 9.6. LCMS: *m/z* [M+H]⁺ 276.0.

4.1.3.10. Synthesis of 7-amino-1-cyclopropyl-3-(4-nitrobenzyl)-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 10).

To a suspension of sodium hydride (60% dispersion in mineral oil) (15.3 mg, 0.383 mmol) in DMF (2 mL) was slowly added compound **7** (50 mg, 0.191 mmol) at 0 °C. After stirring for 30 min, *p*-nitrobenzylbromide (83 mg, 0.383 mmol) was added at 0 °C and the reaction mixture was allowed to room temperature and stirred for 12 h. Volatiles were removed under reduced pressure and the residue was purified by flash chromatography (neutral Al₂O₃) using 0–3% methanol in dichloromethane to yield 61% of **10** as an off-white solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.57 (s, 1H), 8.23 (br s, 2H), 8.17 (d, *J* = 8.7 Hz, 2H), 7.56 (d, *J* = 8.8 Hz, 2H), 7.38 (br s, 2H), 5.16 (s, 2H), 2.85–2.71 (m, 1H), 1.12–1.06 (m, 2H), 0.90–0.73 (m, 2H). LCMS: *m/z* [M+H]⁺ 397.2.

4.1.3.11. Synthesis of 7-amino-3-(4-aminobenzyl)-1-cyclopropyl-2,4-dioxo-1,2,3,4-tetrahydropyrido[2,3-d]pyrimidine-6-carboxamide (Compound 11).

A mixture of **10** (27 mg, 0.068 mmol), SnCl₂ (52 mg, 0.273 mmol) in ethyl acetate/methanol (6 mL, 5:6 ratio v/v) was heated at reflux for 12 h. After cooling to room temperature, the solvent was evaporated and the residue was purified by flash chromatography (neutral Al₂O₃) using 0–5% methanol in dichloromethane to isolate 70% of **11** as an off-white solid. Mp >250 °C. ¹H NMR (400 MHz, DMSO-*d*₆): δ 8.55 (s, 1H), 8.21 (br s, 2H), 7.36 (br s, 2H), 7.02 (d, *J* = 8.3 Hz, 2H), 6.45 (d, *J* = 8.4 Hz, 2H), 4.98 (s, 2H), 4.86 (s, 2H), 2.77 (m, 1H), 1.09 (m, 2H), 0.77 (m, 2H). LCMS: *m/z* [M+H]⁺ 367.1.

4.2. In vitro recombinant kinase inhibition assays

Recombinant human eEF-2K (expressed in bacteria in the absence of λ-phosphatase) was purified as described earlier.^{22,23} Inhibitor dose response assays were performed in Buffer A [25 mM HEPES (pH 7.5), 2 mM DTT, 0.15 μM BSA, 50 mM KAcO, 100 μM EGTA, 150 μM CaCl₂, 200 nM CaM and 10 mM MgCl₂], against 30 μM peptide substrate using 5 nM eEF-2K enzyme, 10 μM [γ-³²P]ATP (100–1000 cpm/pmol) and various concentrations of the inhibitor, in a final reaction volume of 100 μL. The reaction mixture containing the inhibitor and eEF-2K was incubated at 30 °C for 30 min before initiating the assay with peptide and [γ-³²P]ATP. At set time points, 10 μL aliquots were taken and spotted onto P81 cellulose filters (Whatman, 2 × 2 cm). The filter papers were then washed thrice with 50 mM phosphoric acid (15 min each wash), once with acetone (15 min), and dried. The amount of labeled peptide associated with each paper was determined by measuring the cpm on a Packard 1500 scintillation counter. Kinase activity in each case was determined by calculating the rate of phosphorylation of the peptide (μM/s), and dose-response curves for data conforming to inhibition were fit to Eq. 1.

$$V_{\text{obs}}^{\text{app}} = V_{\text{max}}^{\text{app}} - \left(V_{\text{max}}^{\text{app}} \times \frac{[i]}{[i] + IC_{50}} \right) + V_{\infty}^{\text{app}} \quad (1)$$

The parameters are defined as follows: $V_{\text{obs}}^{\text{app}}$, apparent rate; $V_{\text{max}}^{\text{app}}$, apparent rate in the absence of the inhibitor (maximum rate); V_{∞}^{app} , apparent rate at saturating concentration of the inhibitor; $[i]$, concentration of the inhibitor; IC_{50} , inhibitor concentration required to achieve half maximal apparent rate. When $V_{\text{obs}}^{\text{app}}$ is converted to percentage maximal activity, $V_{\text{max}}^{\text{app}}$ is taken as 100.

4.3. Cellular kinase inhibition assays**4.3.1. Cell lines and culture conditions**

The human breast cancer cell line MDA-MB-231 was obtained from American Type Culture Collection (Manassas, VA). Cells were

cultured in DMEM/F12 supplemented with 10% FBS, 50 units/mL penicillin and 50 µg/mL streptomycin. Cell cultures were maintained at 37 °C in a humidified incubator containing 5% CO₂. All cell culture reagents were from Invitrogen or Sigma–Aldrich.

4.3.2. Treatment of cells with stimuli and inhibitors

MDA-MB-231 breast cancer cells were seeded in 6-well plates, and treated when ~80% confluent. To activate the AMPK-eEF-2K axis, cells were treated with 2-DOG as follows. Cells were washed with phosphate buffered saline (PBS, pH 7.4), and then pre-incubated in low-glucose (5.6 mM) DMEM supplemented with 10% FBS for 2 h. Then in the same low-glucose media, cells were initially treated with 75 µM compound **6**, **9**, or **12** for 30 min, followed by incubation ± 25 mM 2-DOG in the presence of the compounds for an additional 30 min. Treatments with the appropriate DMSO controls were also performed.

4.3.3. Cell lysis and western blot analysis

Following treatments, cells were washed twice in ice-cold PBS (pH 7.4), and lysed in ice-cold Buffer B [50 mM HEPES (pH 7.4), 150 mM NaCl, 1.5 mM MgCl₂, 1% Triton X-100, 1 mM EGTA, 100 mM NaF, 10 mM Na pyrophosphate, 1 mM Na₃VO₄ and 10% glycerol], supplemented with PhosSTOP Phosphatase Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN), complete EDTA-free Protease Inhibitor Cocktail (Roche Diagnostics) and Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Lysates were subjected to one freeze-thaw cycle, and then clarified by centrifugation at 15,000g for 15 min. Total protein concentration for each sample was determined by Bradford assay (Bio-Rad Laboratories, Hercules, CA). Western blotting was carried out with 5–10 µg protein. Equal amounts of protein from cell lysate samples were resolved by 10% SDS-PAGE and then transferred to Amersham Hybond-P PVDF membranes (GE Healthcare, Piscataway, NJ). Membranes were blocked with 5% BSA or non-fat dry milk in Tris-buffered saline/Tween 20 (TBST) for 1 h, and then incubated with primary antibodies at 4 °C overnight, according to the manufacturer's protocol. The membranes were washed with TBST and incubated with the appropriate HRP-conjugated secondary antibody at room temperature for 1 h. After washing with TBST, chemiluminescence detection was performed with Amersham ECL Plus™ Western Blotting Detection Reagents (GE Healthcare).

4.3.4. Commercial antibodies

eEF-2K (C-term) (eEF-2K) antibody RabMab® (#1754-1, 1:3000) was purchased from Epitomics (Burlingame, CA). Phospho-eEF2 (Thr56) Antibody (#2331, 1:3000) was obtained from Cell Signaling Technology (Danvers, MA). Anti-eEF2 (C-term) (#07-1382, 1:25,000) and Anti-Actin Antibody, clone C4 (#MAB1501, 1:40,000) were from Millipore (Billerica, MA). Bio-Rad Laboratories supplied Goat Anti-Rabbit IgG (H+L)-HRP Conjugate (#172-1019, 1:2000) and Goat Anti-Mouse IgG (H+L)-HRP Conjugate (#172-1011, 1:2000) secondary antibodies.

Acknowledgments

This research work is supported in part by the grants from the National Institutes of Health (GM59802), and the Welch Foundation (F-1390). R. Edupuganti acknowledges Cancer Prevention and Research Institute of Texas (CPRIT) postdoctoral training award (RP101501).

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.2014.06.050>.

References and notes

- Ryazanov, A. G.; Shestakova, E. A.; Natapov, P. G. *Nature* **1988**, *334*, 170.
- Redpath, N. T.; Price, N. T.; Severinov, K. V.; Proud, C. G. *Eur. J. Biochem.* **1993**, *213*, 689.
- Proud, C. G. *Biochem. J.* **2007**, *403*, 217.
- Leprivier, G.; Remke, M.; Rotblat, B.; Dubuc, A.; Mateo, A. R.; Kool, M.; Agnihotri, S.; El-Naggar, A.; Yu, B.; Somasekharan, S. P.; Faubert, B.; Bridon, G.; Tognon, C. E.; Mathers, J.; Thomas, R.; Li, A.; Barokas, A.; Kwok, B.; Bowden, M.; Smith, S.; Wu, X.; Korshunov, A.; Hielscher, T.; Northcott, P. A.; Galpin, J. D.; Ahern, C. A.; Wang, Y.; McCabe, M. G.; Collins, V. P.; Jones, R. G.; Pollak, M.; Delattre, O.; Gleave, M. E.; Jan, E.; Pfister, S. M.; Proud, C. G.; Derry, W. B.; Taylor, M. D.; Sorensen, P. H. *Cell* **2013**, *153*, 1064.
- Parmer, T. G.; Ward, M. D.; Yurkow, E. J.; Vyas, V. H.; Kearney, T. J.; Hait, W. N. *Br. J. Cancer* **1999**, *79*, 59.
- Bagaglio, D. M.; Hait, W. N. *Cell Growth Differ.* **1994**, *5*, 1403.
- Nilsson, A.; Nygard, O. *Biochim. Biophys. Acta* **1995**, *1268*, 263.
- Ashour, A. A.; Abdel-Aziz, A. A.; Mansour, A. M.; Alpay, S. N.; Huo, L.; Ozpolat, B. *Apoptosis* **2014**, *19*, 241.
- Hait, W. N.; Wu, H.; Jin, S.; Yang, J. M. *Autophagy* **2006**, *2*, 294.
- (a) Gschwendt, M.; Kittstein, W.; Marks, F. *FEBS Lett.* **1994**, *338*, 85; (b) Soltoff, S. P. *Trends Pharmacol. Sci.* **2007**, *28*, 453; (c) Parmer, T. G.; Ward, M. D.; Hait, W. N. *Cell Growth Differ.* **1997**, *8*, 327.
- Cho, S. I.; Koketsu, M.; Ishihara, H.; Matsushita, M.; Nairn, A. C.; Fukazawa, H.; Uehara, Y. *Biochim. Biophys. Acta* **2000**, *1475*, 207.
- Arora, S.; Yang, J. M.; Kinzy, T. G.; Utsumi, R.; Okamoto, T.; Kitayama, T.; Ortiz, P. A.; Hait, W. N. *Cancer Res.* **2003**, *63*, 6894.
- Devkota, A. K.; Tavares, C. D.; Warthaka, M.; Abramczyk, O.; Marshall, K. D.; Kaoud, T. S.; Gorgulu, K.; Ozpolat, B.; Dalby, K. N. *Biochemistry* **2012**, *51*, 2100.
- Lockman, J. W.; Reeder, M. D.; Suzuki, K.; Ostanin, K.; Hoff, R.; Bhoite, L.; Austin, H.; Baichwal, V.; Adam Willardsen, J. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2283.
- Devkota, A. K.; Warthaka, M.; Edupuganti, R.; Tavares, C. D.; Johnson, W. H.; Ozpolat, B.; Cho, E. J.; Dalby, K. N. *J. Biomol. Screen.* **2014**, *19*, 445.
- Chen, Z.; Gopalakrishnan, S. M.; Bui, M. H.; Soni, N. B.; Warrior, U.; Johnson, E. F.; Donnelly, J. B.; Glaser, K. B. *J. Biol. Chem.* **2011**, *286*, 43951.
- Nieto, M. I.; Balo, M. C.; Brea, J.; Caamaño, O.; Cadavid, M. I.; Fernández, F.; Mera, X. G.; López, C.; Rodríguez-Borges, J. E. *Bioorg. Med. Chem.* **2009**, *17*, 3426.
- Hirota, K.; Kitade, Y.; Senda, S. J. *Heterocyclic Chem.* **1985**, *22*, 345.
- Hartshorn, M. J.; Verdonk, M. L.; Chessari, G.; Brewerton, S. C.; Mooij, W. T.; Mortenson, P. N.; Murray, C. W. *J. Med. Chem.* **2007**, *50*, 726.
- Korb, O.; Stützel, T.; Exner, T. E. *J. Chem. Inf. Model.* **2009**, *49*, 84.
- Tavares, C. D.; Edupuganti, R.; Yan, C.; Shi, Y.; Jose, J.; Wang, Q.; Kaoud, T. S.; Cho, E. J.; Ren, P.; Dalby, K. N. manuscript in preparation.
- Tavares, C. D.; O'Brien, J. P.; Abramczyk, O.; Devkota, A. K.; Shores, K. S.; Ferguson, S. B.; Kaoud, T. S.; Warthaka, M.; Marshall, K. D.; Keller, K. M.; Zhang, Y.; Brodbelt, J. S.; Ozpolat, B.; Dalby, K. N. *Biochemistry* **2012**, *51*, 2232.
- Abramczyk, O.; Tavares, C. D.; Devkota, A. K.; Ryazanov, A. G.; Turk, B. E.; Riggs, A. F.; Ozpolat, B.; Dalby, K. N. *Protein Expr. Purif.* **2011**, *79*, 237.
- Proud, C. G.; Wang, X.; Patel, J. V.; Campbell, L. E.; Kleijn, M.; Li, W.; Browne, G. J. *Biochem. Soc. Trans.* **2001**, *29*, 541.
- Browne, G. J.; Finn, S. G.; Proud, C. G. *J. Biol. Chem.* **2004**, *279*, 12220.